Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones - Wikidata - wikimedia - TriplyDB

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

http://www.wikidata.org/entity/Q35858587

about

The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors New targets for therapy in breast cancer: farnesyltransferase inhibitors.Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors Targeting protein prenylation for cancer therapy Anticancer drug targets: growth factors and growth factor signaling.Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.Blocking oncogenic Ras signaling for cancer therapy.Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.Farnesyltransferase inhibitors: mechanism and applications.The search for optimal treatment in relapsed and refractory acute myeloid leukemia.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Emerging drugs for non-small cell lung cancer.Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.Farnesyltransferase inhibitors reverse taxane resistance The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.Novel targeted agents in the treatment of lung cancer.Anatomy of a joint venture: Dana Farber/Partners Cancer Care.The antibody catalysis route to the total synthesis of epothilones.Inhibition of farnesyltransferase: a rational approach to treat cancer?Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents.Mechanisms of Chromosome Congression during Mitosis.Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.Working together: Farnesyl transferase inhibitors and statins block protein prenylation.The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.H-ras localizes to cell nuclei and varies with the cell cycle K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53.

P2860

Q24312194-F343509B-6CC7-43A2-9071-1BE4AD642A58 Q24552386-53CAEF3D-A7AF-4F41-8FBA-DE59D8838CB6 Q24796277-87D74486-2B99-4E65-9248-AF9B9A4D5E73 Q28138265-D6EB6D3C-F5D5-46E7-A768-0615DA66014C Q28371622-17C3F9FC-B25D-42C0-BE5A-CEA3844BA1F3 Q30583965-6654FC96-35FD-4B17-951F-746553E14655 Q32160539-07F0A307-9E89-4241-925A-627B22F768B4 Q33201555-79D0D7A2-CECF-4E30-812B-F69160BA5045 Q33669995-752285E6-68FC-4390-841A-672D5BAF4440 Q33679239-C24D0FEA-27BD-4627-A23F-06FC1C4DACC9 Q33808352-7B09C6EA-E133-49E1-8EAB-906018027BE5 Q33947088-DF1D5022-0774-46FF-B8E0-86691ED45376 Q34311585-147F8B64-AF33-4E5C-828D-C679CD0C2070 Q34325219-E3485E8B-17BF-4C10-B18C-DDD5E47614B9 Q34481874-479C5C80-54D2-41E9-BC5F-4125D1E4A6A8 Q34630777-C9ADAF99-1297-41F3-AA9D-8D2E27603F3F Q34651253-8FD7CFB3-0B66-48B0-96E8-41BC242B9D3F Q35091519-31601F74-437E-49CC-8B34-08C75C7339D5 Q35581167-CFE3D3ED-D1A3-45CE-A00B-06E99D744BC1 Q35621957-7556890E-11B0-43E7-86F0-133BBFF6DFF1 Q35774556-11C12B96-4C34-4E25-BBA2-3069D907B81E Q35774565-DD1ECC07-615E-468D-8328-D780C51532CD Q35790783-85D00F63-44FF-4286-953D-5AE767FADE5F Q36371988-282D6A4C-3E0C-4539-8273-19FC053056AE Q36752669-44D27F39-EBC9-43CA-B050-4E20A824A4F0 Q36828655-CE70B00A-B1FE-4685-9389-E04E629EF173 Q37472121-5B1F494B-8823-4AB3-8C9C-C67F33B778DB Q37728193-FC53F591-01D3-4934-B009-24F9C1EAEA81 Q38915441-C1339F74-B451-4076-8043-F798191F1B5F Q39474160-A13F74C3-8761-4762-A409-1710AACEC20B Q40149906-E3AE6C88-06F6-463A-B71B-400B1BE1911C Q40399733-9D762C6E-3A24-4335-B655-DF0BC74CDEAF Q40455268-5A2EFC34-4A9F-4A61-B03F-DF5373F1CB59 Q40871201-A736E9FB-2F73-4BE6-AFF7-8FBCEFE2307A Q41824137-9D51D063-20FB-4034-A641-3589479877C6 Q42210981-FF289FB9-1269-4CC8-9F5D-E94F402EA8A0 Q42357855-C98E41D0-1E73-4D72-BB62-383AF05C12FD Q42830828-EF7BB653-0E19-4D11-84BF-35734F0BDBD3 Q43514585-1C5B68B9-1702-4C17-824D-B8AC1A67E490 Q44062538-38310562-A9BC-48FC-B6AA-0CEBB43EAC7D

P2860

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

http://www.wikidata.org/entity/Q35858587

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@ast

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@en

type

label

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@ast

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@en

prefLabel

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@ast

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@en

P1433

Q35858587-248901F0-766F-46F9-A11F-F14EA339617D

P1476

Q35858587-20090CA1-7700-47C5-B420-56BA81F079BF

P2093

Q35858587-29E8671B-01ED-47EA-B823-FCB96DB69624

Q35858587-50914968-E349-420B-9793-9E8581B3E59C

Q35858587-5577D884-5922-4F6A-A21C-17BB39C3188C

Q35858587-7654AC69-BEC3-4BF4-9A21-94745685415B

Q35858587-989A0B31-E10D-4783-8D41-19B2E4465259

Q35858587-A3EFB674-E60E-49B1-98CC-D64336071014

Q35858587-C3597667-7EDB-45A5-88B2-4DC6ABEED881

Q35858587-DC7F4068-7C2A-4BAA-85A1-56F66456AB48

P2860

Q35858587-035B2057-235D-401A-8537-080DF602805A

Q35858587-16B589AF-340F-483B-A540-796831F1D3FD

Q35858587-1E8193B1-BC93-49EF-8E80-C137A3628D03

Q35858587-2008B6C7-EF06-45C2-BD09-3D9E3FA5B529

Q35858587-335CBD6C-B0A9-4641-948E-FA731BD5953A

Q35858587-5126E341-C991-4957-8523-7DDC07449246

Q35858587-67FA76C4-F637-47BE-A923-B5D3E417752C

Q35858587-8D2A7CC3-ACAE-4EFD-9E47-16ADEE55A965

Q35858587-A5B52A0A-D540-4062-8E99-3F9A90ACC070

Q35858587-B191A816-CCE7-4E6A-9EF6-9859851ED6B9

P304

Q35858587-C5FDEAA6-B826-44E8-8D4F-9C39B458D635

P31

Q35858587-B62D9172-C0EB-4A86-8A55-0B6FEA2025D6

P356

Q35858587-BA15DF37-DDE4-4FC4-812F-E573A414459F

P407

Q35858587-599B4237-D71C-4A45-B554-158951D604AD

P433

Q35858587-72220F56-9499-4F4C-BC4C-D6B27EBCFF75

P478

Q35858587-A428C127-4293-4EB7-908B-E3B710210D35

P577

Q35858587-9BF894FD-8B08-4AC3-8115-C12EBD84D174

P5875

Q35858587-AA53D232-1D83-4D6F-84EA-C4FCE1C2926A

P698

Q35858587-E17BCB4A-A69E-465A-AE6C-844F9E588BB0

P932

Q35858587-9D1B1875-EBC7-40EE-9342-DBA6FFF22859

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Farnesyl transferase inhibitor ...... ivity to taxol and epothilones

@en

P2093

A Balog

http://www.w3.org/2001/XMLSchema#string

A Oliff

http://www.w3.org/2001/XMLSchema#string

D S Su

http://www.w3.org/2001/XMLSchema#string

L Sepp-Lorenzino

http://www.w3.org/2001/XMLSchema#string

M M Moasser

http://www.w3.org/2001/XMLSchema#string

N E Kohl

http://www.w3.org/2001/XMLSchema#string

N Rosen

http://www.w3.org/2001/XMLSchema#string

S J Danishefsky

http://www.w3.org/2001/XMLSchema#string

P2860

Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice

Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.

Development of inhibitors of protein farnesylation as potential chemotherapeutic agents.

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

P304

1369-1374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.95.4.1369

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

1998-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235612901

http://www.w3.org/2001/XMLSchema#string

P698

9465021

http://www.w3.org/2001/XMLSchema#string

P932

19006

http://www.w3.org/2001/XMLSchema#string